Related Experiment Videos
Multi-centered clinical evaluation of oxepinac against peripheral arthropathy particularly osteoarthritis
Abstract:
Clinical evaluation in phase II of 6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid (oxepinac) has been made in a single-blind trial in the treatment of osteoarthritis, 135 patients with mainly gonitis. Male 31, female 104, and the age distribution are 37--82 years and 62 years in average. Three groups of the doses, 75 mg, 150 mg, 300 mg daily, respectively, were administered for two weeks. Parameters studied included subjective relief of pain, range of joint motion, "patients preference" and biochemical studies. Oxepinac resulted in definite relief of pain compared with preceding medication and was tolerated well without serious side effect. The dose 150 mg was estimated most favourable. It is concluded that oxepinac offers an effective and well-tolerated alternative to drugs at present being used in the treatment of painful osteoarthritis.
Insights
Oxepinac (6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid) effectively relieved osteoarthritis pain in a phase II trial. The 150 mg dose was most favorable, showing good tolerability without serious side effects.
Area of Science:
- Pharmacology
- Rheumatology
- Clinical Trials
Background:
- Osteoarthritis is a prevalent degenerative joint disease causing pain and reduced mobility.
- Current treatments for osteoarthritis have limitations in efficacy and side effect profiles.
- There is a need for well-tolerated and effective therapeutic alternatives.
Purpose of the Study:
- To evaluate the efficacy and safety of 6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid (oxepinac) in patients with osteoarthritis.
- To determine the optimal dosage of oxepinac for osteoarthritis treatment.
- To compare oxepinac's effectiveness against previous medications.
Main Methods:
- A single-blind, phase II clinical trial involving 135 osteoarthritis patients (mainly gonitis).
- Patients were randomized into three groups receiving daily doses of oxepinac: 75 mg, 150 mg, or 300 mg for two weeks.
- Outcome measures included subjective pain relief, joint range of motion, patient preference, and biochemical markers.
Main Results:
- Oxepinac demonstrated significant pain relief compared to prior treatments.
- The 150 mg daily dose was identified as the most favorable.
- The drug was well-tolerated, with no serious adverse events reported during the trial.
Conclusions:
- Oxepinac presents a promising and safe alternative for managing painful osteoarthritis.
- The 150 mg dosage is recommended for further investigation and potential clinical use.
- Further research into oxepinac's long-term effects and broader applications in rheumatology is warranted.